APS.TO - Aptose Biosciences Inc.
| Previous Close | 4.12 |
| Open | 4.12 |
| Bid | 3.91 x 0 |
| Ask | 3.93 x 0 |
| Day's Range | 3.89 - 4.12 |
| 52 Week Range | 1.64 - 5.97 |
| Volume | 25,605 |
| Avg. Volume | 39,541 |
| Market Cap | 130.979M |
| Beta | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.60 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.22 |
- Zacks•7 hours ago
New Strong Sell Stocks for July 23rd
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•12 days ago
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
- ACCESSWIRE•12 days ago
Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- GlobeNewswire•13 days ago
Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806
SAN DIEGO, TORONTO, and SEOUL, July 10, 2018-- Aptose Biosciences Inc., today announced that the Japan Patent Office has issued Japanese Patent No. 6325573 for CG-806. The granted patent claims various ...
- GlobeNewswire•14 days ago
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day
SAN DIEGO and TORONTO, July 09, 2018-- Aptose Biosciences Inc. today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief ...
- GlobeNewswire•24 days ago
FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
Aptose Biosciences Inc. (APTO) (APS.TO) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has lifted the clinical hold on APTO-253, Aptose’s investigational drug for hematologic cancers. Up to fifteen clinical centers are expected to participate in the Phase 1b trial, and the screening and dosing will resume as soon as practicable for patients with relapsed or refractory AML or with high risk myelodysplastic syndromes (MDS).
- GlobeNewswire•last month
Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association
STOCKHOLM, Sweden and SAN DIEGO, June 15, 2018-- Aptose Biosciences Inc. today announced the presentation of preclinical data demonstrating that CG-806, a highly potent pan-FLT3/pan-BTK inhibitor, exhibits ...
- Simply Wall St.•last month
Aptose Biosciences Inc’s (TSE:APS) Profit Outlook
Aptose Biosciences Inc’s (TSX:APS): Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company’s loss has recently broadenedRead More...
- GlobeNewswire•last month
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China
Aptose Biosciences Inc. (APTO) (APS.TO) today announced that they have entered into a license agreement with CrystalGenomics, Inc. (083790.KQ) for China rights to CG-806 (including People’s Republic of China, Hong Kong and Macau). Aptose will now own worldwide rights (excluding Korea) to develop and commercialize CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B-cell malignancies and other hematologic malignancies.
- Baystreet•last month
Crown Point at 52-Week High on Buying Apco
Crown Point Energy Inc. (V.CWV) hit a new 52-week high of 70 cents Friday. Crown Point has closed its ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Aptose Biosciences, Fennec Pharmaceuticals, Valeant Pharmaceuticals and BELLUS Health
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
- GlobeNewswire•2 months ago
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
SAN DIEGO and TORONTO, June 05, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the ...
- GlobeNewswire•2 months ago
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253
Aptose Biosciences Inc. (APTO) (APS.TO) today announced the publication of preclinical data elucidating the mechanism of action of APTO-253, the company’s clinical stage anticancer product candidate. The first publication, entitled “APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression and induces DNA damage in acute myeloid leukemia cells,” demonstrates that the APTO-253 small molecule anticancer agent inhibits expression of the MYC oncogene and depletes cells of the MYC protein, triggers the DNA repair and stress response pathways, and promotes programmed cell death (apoptosis) in acute myeloid leukemia (AML) cell lines and fresh bone marrow samples derived from patients with AML and other hematologic malignancies that often depend on MYC upregulation.
- Baystreet•2 months ago
Stocks in play: Aptose Biosciences Inc.
Has entered into a Common Share Purchase Agreement of up to $20 Million U.S. with Aspire Capital Fund, ...
- GlobeNewswire•2 months ago
APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
Aptose will control the timing and amount of the sale of common shares of Aptose to Aspire Capital. On any business day, Aptose shall have the right to direct Aspire Capital to purchase up to 200,000 common shares with a value not exceeding US$500,000.
- GlobeNewswire•2 months ago
Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association
SAN DIEGO and TORONTO, May 17, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that ...
- GlobeNewswire•2 months ago
Aptose Reports Results for the First Quarter Ended March 31, 2018
Aptose Biosciences Inc. (“Aptose” or the “Company”) (APTO) (APS.TO), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended March 31, 2018 and reported on corporate developments. Total cash and cash equivalents and investments as of March 31, 2018 were $16.2 million (which, based on current operations, provide the Company with sufficient resources to fund research and development and operations into Q2 2019). “In parallel, new preclinical data on CG-806 presented at AACR demonstrate its breadth and potency of activity against patient-derived AML and CLL cells and superiority to other kinase inhibitors.
- GlobeNewswire•3 months ago
Aptose Exercises Early Option for CG-806 License From CrystalGenomics
Aptose Biosciences Inc. (APTO) (APS.TO) and CrystalGenomics, Inc. (083790.KQ) today announced that Aptose exercised its option under the 2016 Option Agreement to exclusively license CG-806, a first-in-class, non-covalent pan-inhibitor of the Bruton’s tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3) from CrystalGenomics, Inc. CG-806 is being developed as a highly potent, oral small molecule for acute myeloid leukemia (AML), B-Cell malignancies and other hematologic malignancies.
- ACCESSWIRE•3 months ago
Today’s Research Reports on Fennec Pharmaceuticals, Aptose Biosciences, TSO3 and ImmunoVaccine
NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
- GlobeNewswire•3 months ago
Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018
SAN DIEGO and TORONTO, May 01, 2018-- Aptose Biosciences Inc., a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer ...
- GlobeNewswire•3 months ago
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
SAN DIEGO and TORONTO, April 25, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the ...
